High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a

2014 ◽  
Vol 28 (4) ◽  
pp. 451-456 ◽  
Author(s):  
Takahito Moriyama ◽  
Mitsuyo Itabashi ◽  
Takashi Takei ◽  
Hiroshi Kataoka ◽  
Masayo Sato ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Risk Factor ◽  
Kidney Disease ◽  
Uric Acid Level ◽  
Acid Level ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
High Uric Acid ◽  
High Uric Acid Level

scholarly journals Gambaran Kadar Asam Urat pada Pasien Penyakit Ginjal Kronik Stadium 5 yang Belum Menjalani Hemodialisis

2017 ◽  
Vol 5 (2) ◽  
Author(s):  
Inri N.R.I. Mantiri ◽  
Glady I. Rambert ◽  
Mayer F. Wowor
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Risk Factor ◽  
Kidney Disease ◽  
Uric Acid Level ◽  
Acid Level ◽  
Food Source ◽  
The Body ◽  
Renal Diseases ◽  
Blood Samples

Abstract: Uric acid is the end product of purine metabolism derived from metabolism in the body and from outside the body (food source). Hyperuricemia is a condition of uric acid level above normal (3.5-7 mg/dL in males and 2.6-6 mg/dL in females). Hyperuricemia due to renal diseases is a risk factor of the progressivity of the disease. This study was aimed to obtain the profile of uric acid level in patients with stage 5 non-dialysis chronic kidney disease (CKD). This was a descriptive observational study. Samples were 35 blood samples of in-patients and out-patients with stage 5 non-dialysis CKD at Prof. Dr. R. D. Kandou Hospital and Advent Hospital Manado during Deember 2015 to January 2016. The laboratory test showed that 80% of patients had increased uric acid levels >7 mg/dL. Conclusion: Most patients with stage 5 non-dialysis chronic kidney disease had increased uric acid levels.Keywords: uric acid, stage 5 non-dialysis chronic kidney disease Abstrak: Asam urat merupakan produk akhir metabolism purin yang berasal dari baik dari metabolism dalam tubuh dan berasal dari luar tubuh (makanan). Hiperurisemia adalah keadaan dimana kadar asam urat darah di atas nilai normal (3,5-7 mg/dL pada pria dan 2,6-6 mg/dL pada wanita). Hiperuresemia yang disebabkan oleh penyakit ginjal dianggap sebagai factor risiko progresivitas penyakit ginjal. Penelitian ini bertujuan untuk mengetahui gambaran kadar asam urat pada pasien penyakit ginjal kronik stadium 5 non-dialisis. Jenis penelitian ialah deskriptif observasional. Sampel penelitian ialah sampel darah dari semua pasien rawat jalan maupun rawat inap yang menderita penyakit ginjal kronik stadium 5 non-dialisis dalam kurun waktu Desember 2015-Januari 2016 di RSUP Prof. Dr. R. D. Kandou dan RS Advent Manado. Hasil pemeriksaan laboratorium dari 35 pasien yang terdiagnosis penyakit ginjal kronik stadium 5 non-dialisis memperlihatkan peningkatan kadar asam urat >7 mg/dL pada 80% sampel. Simpulan: Terdapat peningkatan kadar asam urat pada sebagian besar pasien penyakit ginjal kronik stadium 5 non-dialisis.Kata kunci: asam urat, penyakit ginjal kronik stadium 5 non dialisis

scholarly journals Study of Serum Uric Acid in Different Stages of Chronic Kidney Disease

2021 ◽  
pp. 70-79
Author(s):  
Shahida Akhter ◽  
A. S. M. Rizwan
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Medical College ◽  
Bonferroni Test

Background: Hyperuricaemia is a metabolic marker of decreased renal function in chronic kidney disease (CKD). It increases cardiovascular, cerebrovascular and mortality risk in patients with CKD. Objectives: To estimate serum uric acid level in different stages of CKD. Methods: The present study was a cross sectional analytical study and was conducted in the Department of Physiology, Dhaka Medical College, Dhaka from July 2012 to June 2013 on 300 participants. They were divided into group A (150 control healthy participants) and group B (150 diagnosed cases of CKD). Serum creatinine and serum uric acid levels were measured by auto analyzer in Department of Pathology, Dhaka Medical College. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine level by Modification of Diet in Renal Disease (MDRD) equation. For statistical analysis unpaired Student “t” test, one way ANOVA test, Bonferroni test, Pearson’s correlation coefficient (r) test and Linear regression were performed using SPSS for windows version 20. Result: In this study, serum uric acid level was significantly (p<0.05) higher and eGFR were significantly lower in study groups than that of control group. There was gradual rise of serum uric acid level in CKD subjects from stage I to V. A significant inverse correlation was observed between serum uric acid level and eGFR. Serum uric acid level increased 0.048 mg/dl for each ml/min/1.73m2 decrease of eGFR. Conclusion: This study concludes that serum uric acid level increases gradually in accordance with the higher stages of CKD. There is a negative correlation of serum uric acid with eGFR in all stages of CKD which was statistically significant (p<0.05). Screening of serum uric acid level in different stages of CKD may be beneficial for assessing renal damage as well as prediction of co-morbidities associated with it.

scholarly journals Effect of Allopurinol on Inflammatory Markers in Chronic Kidney Disease Patients with Asymptomatic Hyperuricaemia

2017 ◽  
Vol 26 (1) ◽  
pp. 12-24
Author(s):  
ASM Tanim Anwar ◽  
Md Nizamuddin Chowdhury ◽  
Md Nazrul Islam ◽  
Parvez Iftekher Ahmed ◽  
Sohely Ahmed Sweety ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Treatment Group ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Control Group ◽  
Base Line

This was a hospital based prospective, interventional study which included CKD stage 3- 5 patients with higher level of uric acid (male>7mg/dl, female>6mg/dl). The objective of the study was to evaluate the effect of allopurinol on inflammatory markers in patients with chronic kidney disease (stage 3-5) with asymptomatic hyperuricaemia. One hundred and twenty patients were distributed in two groups. Sixty patients were placed in treatment group and sixty in control group. Purposive sampling technique was followed. In the study mean age was 49 (±9) years in treatment group and 45 (±11) years in control groups. Male were predominant in both groups. There were no significant difference in baseline characteristics between treatment group and control group (p>0.05). Sixty patients of treatment group were administered a dose of 100 mg/d of allopurinol. Follow up assessment was done at basally, at 4 months and at 8 month after starting treatment. No significant differences were seen between baseline SBP, DBP, Hb and HbA1c with 4th month and 8th month follow up in both treatment group and control group, but mean Hb was significantly decreased in control group from the baseline after 8 month. No significant change was found in case of mean ESR at 4th and 8th month in any group. But base line mean CRP was significantly reduced in treatment group and increased in control group at 4th and 8th month of follow up. Serum uric acid was decreased in treatment group while it was significantly raised from the base line at 4th month and 8th month in control group. While comparing between two groups results showed means of serum uric acid and CRP were significantly decreased in treatment group compared to control group after 8th month. There was a positive correlation between Uric Acid with CRP level after 8 month of allopurinol treatment although this finding was not statistically significant. So, allopurinol may have a protective role in CKD by decreasing serum uric acid level and reduction of inflammatory response in patients with chronic kidney disease stage 3 - 5 with asymptomatic hyperuricaemia.J Dhaka Medical College, Vol. 26, No.1, April, 2017, Page 12-24

Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements

2014 ◽  
Vol 28 (4) ◽  
pp. 457-462 ◽  
Author(s):  
Yu-Ching Chou ◽  
Jen-Chun Kuan ◽  
Tsan Yang ◽  
Wan-Yun Chou ◽  
Po-Chien Hsieh ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Cohort Study ◽  
Kidney Disease ◽  
Uric Acid Level ◽  
Acid Level ◽  
Repeated Measurements

scholarly journals Serum Uric Acid Level and Endothelial Dysfunction in Patients with Nondiabetic Chronic Kidney Disease

2011 ◽  
Vol 33 (4) ◽  
pp. 298-304 ◽  
Author(s):  
Mehmet Kanbay ◽  
Mahmut Ilker Yilmaz ◽  
Alper Sonmez ◽  
Faruk Turgut ◽  
Mutlu Saglam ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Endothelial Dysfunction ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level

scholarly journals Effect of Allopurinol in Chronic Kidney Disease Progression in Asymptomatic Hyperuricaemic Subjects

2017 ◽  
Vol 25 (1) ◽  
pp. 5-15
Author(s):  
ASM Tanim Anwar ◽  
Md Nizamuddin Chowdhury ◽  
Md Nazrul Islam ◽  
Parvez Iftekher Ahmed ◽  
Sohely Ahmed Sweety ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Treatment Group ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Control Group ◽  
And Control

This was a hospital based prospective, interventional study which included CKD stage 3- 5 patients with higher level of uric acid (male>7mg/dl, female>6mg/dl). The objective of the study was to evaluate the effect of allopurinol in chronic kidney disease (stage 3-5) progression in asymptomatic hyperuricaemic patients.One hundred and twenty patients were distributed in two groups. Sixty patients were placed in treatment group and sixty in control group. Purposive sampling technique was followed. In the study mean age was 49 (±9) years in treatment group and 45 (±11) years in control groups. Male were predominant in both groups. There were no significant difference in baseline characteristics between treatment group and control group (p>0.05). Sixty patients of treatment group were administered a dose of 100 mg/d of allopurinol. Follow up assessment was done at basally, at 4 months and at 8 month after starting treatment. No significant differences were seen between baseline SBP, DBP, Hb and HbA1c with 4th month and 8th month follow up in both treatment group and control group, but mean Hb was significantly decreased in control group from the baseline after 8 month. Serum uric acid was decreased in treatment group while it was significantly raised from the base line at 4th month and 8th month in control group. In treatment group serum creatinine was decreased and eGFR was raised from the baseline after 8 month. On the other hand, in control group serum creatinine was significantly raised and eGFR was significantly decreased from the baseline at 8th month. While comparing between two groups results showed means of serum uric acid was significantly decreased in treatment group compared to control group after 8th month. There was a negative correlation between Uric Acid with eGFR after 8 month of allopurinol treatment although this finding was not statistically significant. So, allopurinol may have a protective role in CKD progression by decreasing serum uric acid level in patients with chronic kidney disease stage 3 - 5 with asymptomatic hyperuricaemia.J Dhaka Medical College, Vol. 25, No.1, April, 2016, Page 5-15

scholarly journals A REVIEW ON THE EFFECT OF FEBUXOSTAT IN CHRONIC KIDNEY PATIENTS, IT’S SIGNIFICANCE IN eGFR, URIC ACID AND ALBUMINURIA.

2019 ◽  
Vol 7 (2) ◽  
Author(s):  
Jinsu Deena Jose ◽  
Mathew George ◽  
Lincy Joseph
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Uric Acid ◽  
Kidney Disease ◽  
Uric Acid Level ◽  
Acid Level ◽  
Oxidase Inhibitor ◽  
Xanthine Oxidase Inhibitor ◽  
Irreversible Reduction ◽  
Risk Of Progression

Chronic kidney disease is defined as the abnormality of the kidney structure or function for≥ 3 months and is associated with an irreversible reduction of the excretory and the endocrine functions of the kidney. An important risk factor for the development and progression of CKD is hyperuricemia. Hyperuricemia can occur as a result of the increased production or the reduced secretion of uric acid. Increased uric acid level is significantly associated with a greater decline in renal function and there is a higher risk of progression into kidney failure. Febuxostat is a nonpurine xanthine oxidase inhibitor for the treatment of hyperuricemia in patients with chronic kidney disease. It reduces serum uric acid concentrations by blocking the transformation of hypoxanthine to xanthine and xanthine to uric acid. Febuxostat is mainly metabolized in the liver and excreted through both urine and feces. Renal adjustment is also not required in CKD patients with mild to moderately reduced eGFR as it is metabolized mainly by glucuronidation and oxidation in the liver and well excreted by both urinary and fecal routes. Recent studies show that, in addition to lowering the uric acid level, febuxostat preserves the eGFR. Keywords:  Chronic kidney disease, hyperuricemia, febuxostat, eGFR

Sign in / Sign up

Export Citation Format

Share Document